DMAC Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.180

-0%

-0.193

+7.41%

-0.207

+14.82%

Estimates Revision

The market is revising No Change the revenue expectations for DiaMedica Therapeutics Inc. (DMAC) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 16.24%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+16.24%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast DMAC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DMAC is 17.00 USD with a low forecast of 12.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

12.00

Averages

17.00

High

25.00

Current: 0.000

Low

12.00

Averages

17.00

High

25.00

Lake Street

Buy

maintain

$14

2026-01-05

New

Reason

Lake Street

Price Target

$14

2026-01-05

New

maintain

Buy

Reason

Lake Street calls DiaMedica Therapeutics a top idea in the analyst's coverage universe for the 2026, citing a belief that DiaMedica is positioned to deliver "multiple meaningful catalysts" over the next 12-18 months. The firm keeps a Buy rating and $14 price target on DiaMedica shares.

Cantor Fitzgerald

Josh Schimmer

Overweight

initiated

$25

2025-11-14

Reason

Cantor Fitzgerald

Josh Schimmer

Price Target

$25

2025-11-14

initiated

Overweight

Reason

Cantor Fitzgerald analyst Josh Schimmer initiated coverage of DiaMedica Therapeutics with an Overweight rating and $25 price target. DiaMedica has begun to generate very compelling data for DM199 for treatment of pre-eclampsia, with key opinion leaders indicating a very high unmet need and a very high degree of enthusiasm for this product, the analyst tells investors in a research note. The firm estimates peak sales reaching more than $1B by 2033, but believes this will prove quite conservative.

Cantor Fitzgerald

Josh Schimmer

Overweight

initiated

$25

2025-11-14

Reason

Cantor Fitzgerald

Josh Schimmer

Price Target

$25

2025-11-14

initiated

Overweight

Reason

Cantor Fitzgerald analyst Josh Schimmer initiated coverage of DiaMedica Therapeutics with an Overweight rating and $25 price target.

TD Cowen

initiated

2025-10-30

Reason

TD Cowen

Price Target

2025-10-30

initiated

Reason

TD Cowen initiated coverage of DiaMedica Therapeutics with a Buy rating and no price target. The firm says the interim proof of concept data indicates DM199 does not cross the placenta and is a potent vasodilator in preeclampsia, with early signs of enhanced placental perfusion. Key opinion leaders are "enthusiastic" for the potential to treat both hypertension and endothelial dysfunction to drastically improve maternal-fetal outcomes, the analyst tells investors in a research note. TD sees potential $1B in peak sales in early onset preeclampsia alone.

H.C. Wainwright

NULL -> Buy

upgrade

$10 -> $12

2025-07-18

Reason

H.C. Wainwright

Price Target

$10 -> $12

2025-07-18

upgrade

NULL -> Buy

Reason

H.C. Wainwright raised the firm's price target on DiaMedica Therapeutics to $12 from $10 and keeps a Buy rating on the shares. The firm says that with the positive interim results from Part 1a of the Phase 2 study, there is "tangible evidence" for the therapeutic potential of DM199 across achieved pre-specified efficacy and safety endpoints from the dose escalation.

Lake Street

Buy

maintain

$11 -> $14

2025-07-18

Reason

Lake Street

Price Target

$11 -> $14

2025-07-18

maintain

Buy

Reason

Lake Street raised the firm's price target on DiaMedica Therapeutics to $14 from $11 and keeps a Buy rating on the shares after the company announced interim results from Part 1a of the Phase 2 study of DM199 for the treatment of preeclampsia that the firm sees "materially" improving the prospects for DM199 in this indication.

Valuation Metrics

The current forward P/E ratio for DiaMedica Therapeutics Inc (DMAC.O) is -9.95, compared to its 5-year average forward P/E of -5.20. For a more detailed relative valuation and DCF analysis to assess DiaMedica Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.20

Current PE

-9.95

Overvalued PE

-2.56

Undervalued PE

-7.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.01

Current EV/EBITDA

-8.12

Overvalued EV/EBITDA

-0.22

Undervalued EV/EBITDA

-5.81

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

DMAC News & Events

Events Timeline

No data

News

2.0

2025-12-19NASDAQ.COM

Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers

9.0

2025-12-18Newsfilter

DiaMedica Engages FDA for DM199 Preclinical Study Clarity

2.0

2025-12-09NASDAQ.COM

After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences

People Also Watch

Frequently Asked Questions

What is DiaMedica Therapeutics Inc (DMAC) stock price today?

The current price of DMAC is 8.16 USD — it has decreased -2.28 % in the last trading day.

What is DiaMedica Therapeutics Inc (DMAC)'s business?

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.

What is the price predicton of DMAC Stock?

What is DiaMedica Therapeutics Inc (DMAC)'s revenue for the last quarter?

DiaMedica Therapeutics Inc revenue for the last quarter amounts to -9.03M USD, increased 31.24 % YoY.

What is DiaMedica Therapeutics Inc (DMAC)'s earnings per share (EPS) for the last quarter?

DiaMedica Therapeutics Inc. EPS for the last quarter amounts to -27542000.00 USD, increased 514.91 % YoY.

What changes have occurred in the market's expectations for DiaMedica Therapeutics Inc (DMAC)'s fundamentals?

How many employees does DiaMedica Therapeutics Inc (DMAC). have?

DiaMedica Therapeutics Inc (DMAC) has 27 emplpoyees as of January 10 2026.

What is DiaMedica Therapeutics Inc (DMAC) market cap?

Today DMAC has the market capitalization of 424.95M USD.